Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Share-based Compensation (2020 - 2025)

Janux Therapeutics (JANX) has disclosed Share-based Compensation for 6 consecutive years, with $9.5 million as the latest value for Q4 2025.

  • Quarterly Share-based Compensation rose 52.22% to $9.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $40.2 million through Dec 2025, up 21.81% year-over-year, with the annual reading at $40.2 million for FY2025, 21.81% up from the prior year.
  • Share-based Compensation for Q4 2025 was $9.5 million at Janux Therapeutics, up from $9.0 million in the prior quarter.
  • The five-year high for Share-based Compensation was $15.4 million in Q3 2024, with the low at $123000.0 in Q1 2021.
  • Average Share-based Compensation over 5 years is $5.9 million, with a median of $5.0 million recorded in 2022.
  • The sharpest move saw Share-based Compensation soared 63750.0% in 2021, then plummeted 41.22% in 2025.
  • Over 5 years, Share-based Compensation stood at $2.9 million in 2021, then skyrocketed by 42.83% to $4.2 million in 2022, then grew by 6.61% to $4.5 million in 2023, then surged by 39.44% to $6.3 million in 2024, then skyrocketed by 52.22% to $9.5 million in 2025.
  • According to Business Quant data, Share-based Compensation over the past three periods came in at $9.5 million, $9.0 million, and $11.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.